Almirall and Forest to expand aclidinium COPD franchise with Phase III combination trials
This article was originally published in Scrip
Executive Summary
Almirall and its US partner Forest Laboratories are expanding the franchise for their chronic obstructive pulmonary disease (COPD) treatment, aclidinium bromide (Eklira), through the start of a Phase III programme investigating a fixed dose combination (FDC) of the compound with formoterol fumarate.